Review: The coming 15 years in gynaecological pathology: digitisation, artificial intelligence, and new technologies

It’s clearly a very timely discussion with many recent articles reviewing the complexities of the tumor microenvironment and overall tumor heterogeneity that have been implicated in late-stage clinical failures, underscoring an urgent need for tests that accurately predict response to the growing number of available therapies.

If you stand too close to the painting for too long observing all the details, you begin to lose sight of what those brush strokes have created. Only when you step back to take in the scene can you have a full understanding and appreciation for how the individual elements come together to create a work of art.

I have learned in my career that there is a special recipe for making young companies successful. You need to have an amazing product that enables customers to accomplish their goals in a better way than their current method.

It is clear that “zoom fatigue” has set in, and some of the novelty of virtual conferences has worn off in the past year; having said that, they are likely here to stay, even as in-person events return with hybrid events in 2022.

Adapted from a line in “Ode to a Mouse” from fellow countryman Robert Burns, the phrase, “the best-laid plans of mice and men often go awry”, indicate that no matter how carefully a project is planned, something may still go wrong with it unfortunately speaks to the reality of clinical trials for novel therapeutics, with approximately only 11% of drugs that begin phase I clinical trials eventually being licensed.

GEN: If I were to design my own panel for immunofluorescence, what are the main considerations, given everything you’ve suggested during the webinar for validation? Angela: There are several things one needs to think about when you build a new panel for multiplexed immunofluorescence. You need to consider the abundance of the targets to be

As I approach my one-year anniversary with Ultivue, I am excited to be part of a vibrant, rapidly growing company committed to transforming anatomic pathology with our next generation staining technology, InSituPlex®.

I’ve always been curious, with a need to be on the cutting edge of scientific innovation, so after a successful academic career I moved to the rapidly evolving world of biotech. A 15-year journey in this space ultimately led me to Ultivue, their novel InSituPlex® assay, and following advances in tissue multiplexing.